Abstract | OBJECTIVES: BACKGROUND: METHODS: RESULTS: Risk for major bleeding or clinically relevant nonmajor bleeding was reduced with both dabigatran dual therapies compared with warfarin triple therapy in both the prior OAC use group (hazard ratios: 0.58 [95% confidence interval (CI): 0.42 to 0.81] and 0.61 [95% CI: 0.41 to 0.92] with 110 and 150 mg dabigatran, respectively) and the OAC-naive group (hazard ratios: 0.49 [95% CI: 0.38 to 0.63] and 0.76 [95% CI: 0.59 to 0.97] with 110 and 150 mg dabigatran) (p for interaction = 0.42 and 0.37, 110 and 150 mg dabigatran, respectively). The risk for thromboembolic events seemed similar with dabigatran dual therapy (both doses) and warfarin triple therapy across subgroups. CONCLUSIONS:
Bleeding risk was reduced with dabigatran dual therapy versus warfarin triple therapy in patients with atrial fibrillation after PCI, regardless of whether they were prior OAC users or OAC treatment naive. These results suggest that it is also safe to switch patients on OAC pre-PCI to dabigatran dual therapy post-PCI.
|
Authors | Jurrien M Ten Berg, Anne de Veer, Jonas Oldgren, Philippe Gabriel Steg, Dmitry A Zateyshchikov, Petr Jansky, Ki-Bae Seung, Stefan H Hohnloser, Gregory Y H Lip, Matias Nordaby, Eva Kleine, Deepak L Bhatt, Christopher P Cannon, RE-DUAL PCI Steering Committee and Investigators |
Journal | JACC. Cardiovascular interventions
(JACC Cardiovasc Interv)
Vol. 12
Issue 23
Pg. 2331-2341
(12 09 2019)
ISSN: 1876-7605 [Electronic] United States |
PMID | 31806214
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Anticoagulants
- Platelet Aggregation Inhibitors
- Warfarin
- Clopidogrel
- Ticagrelor
- Dabigatran
- Aspirin
|
Topics |
- Administration, Oral
- Aged
- Aged, 80 and over
- Anticoagulants
(administration & dosage, adverse effects)
- Aspirin
(administration & dosage)
- Atrial Fibrillation
(diagnosis, drug therapy, mortality)
- Clopidogrel
(administration & dosage)
- Coronary Artery Disease
(diagnostic imaging, mortality, therapy)
- Dabigatran
(administration & dosage)
- Drug Substitution
(adverse effects)
- Drug Therapy, Combination
- Female
- Hemorrhage
(chemically induced, diagnosis)
- Humans
- Male
- Middle Aged
- Percutaneous Coronary Intervention
(adverse effects, mortality)
- Platelet Aggregation Inhibitors
(administration & dosage, adverse effects)
- Risk Factors
- Ticagrelor
(administration & dosage)
- Time Factors
- Treatment Outcome
- Warfarin
(administration & dosage)
|